Last updated: July 28, 2026
IOBENGUANE SULFATE I 131 clinical trials update, market analysis, and projections
Executive summary: Iobenguane sulfate I 131 (marketed in the US as Azedra) has moved through late-stage development with FDA approval and ongoing real-world use. Current commercial exposure depends on (1) US uptake in refractory or relapsed neuroblastoma and metastatic pheochromocytoma/paraganglioma workflows, (2) competing systemic options (rituximab-based regimens, anti-GD2 antibodies, chemotherapy backbones, and other radiopharmaceuticals), and (3) payer coverage and access constraints typical for targeted radiopharmaceuticals. Public patent, trial, and commercial disclosures remain fragmented; the most business-relevant view is anchored to FDA-labeled indications, ongoing registrational and postmarketing commitments, and pipeline activity around next-generation radioligand competitors.
What is iobenguane sulfate I 131 (Azedra) used for and what is its FDA status?
Labeled indications (US, FDA-approved). Azedra is a radiopharmaceutical indicated for:
- Neuroblastoma: Treatment of adult and pediatric patients 12 years of age and older with relapsed or refractory high-risk neuroblastoma, who have progressed during or after standard therapies or who are not candidates for those therapies. (FDA label)
- Pheochromocytoma and paraganglioma (PPGL): Treatment of adult patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma that are refractory to or have progressed following iodine-avid imaging or other systemic therapies. (FDA label)
Regulatory framework that shapes uptake.
- Azedra is administered following thyroid blockade, with specific dosing and preparatory steps.
- Uptake depends on availability of nuclear medicine infrastructure and local radiopharmacy workflows and the ability to deliver radiopharmaceutical dosing on schedule.
- Access is sensitive to payer prior authorization and site-level throughput.
Core clinical rationale. Iobenguane is an analog of norepinephrine taken up by the NET (norepinephrine transporter), enabling targeted delivery of iodine-131 emissions to neuroendocrine tumors.
Key references (FDA label and prescribing information).
Azedra prescribing information and FDA label sections for indications, dosing, preparation, and safety are the anchor for clinical use and commercialization assumptions. [1]
What clinical trials support Azedra and what is the latest status across indications?
Program structure. Iobenguane I 131 clinical development has been built around single-arm, response-focused studies, consistent with the disease rarity and high unmet need in refractory neuroblastoma and PPGL.
Neuroblastoma evidence base
Design type. Predominantly response-driven trials in relapsed/refractory high-risk neuroblastoma, with endpoints aligned to tumor response and survival measures supported by historical controls.
Business impact.
- Single-arm evidence increases regulatory speed but also makes real-world benchmarking critical for payers and treatment planning.
- Adoption depends on whether outcomes translate into durable remissions relative to evolving anti-GD2 and other salvage strategies.
PPGL evidence base
Design type. Response-focused radiopharmaceutical studies in metastatic or unresectable PPGL after progression or refractoriness to prior options.
Business impact.
- For PPGL, radiopharmaceutical positioning depends on how iobenguane uptake compares to alternative imaging and targeted strategies.
- Uptake is highly influenced by iodine avidity, patient selection, and imaging protocols.
What “update” means for investors and planners
Because Azedra is already approved, “trial updates” for market projections usually reduce to:
- Postmarketing requirements/commitments tied to manufacturing, safety monitoring, and long-term follow-up.
- Additional real-world cohorts and registry analyses (where publicly available).
- Competing radiopharmaceutical trial readouts that could shift share.
Most actionable status datapoints for Azedra forecasting come from:
- continued FDA label utilization patterns
- ongoing radiopharmaceutical competitor development
- payer coverage announcements and utilization trends in neuro-oncology and endocrine oncology.
Source anchor: FDA labeling and clinical-trial evidence summarized in prescribing information. [1]
How big is the addressable market for iobenguane sulfate I 131 in neuroblastoma and PPGL?
Market segmentation logic (demand drivers).
- Patient pool size for relapsed/refractory high-risk neuroblastoma in eligible age bands (12+ in US label).
- Selection constraints tied to “iodine avidity” and logistics for radiopharmaceutical therapy.
- Line of therapy timing: Azedra is typically used after progression on standard approaches.
- Repeat treatment policy and dosing schedules as reflected in label guidance.
- Site capacity for radiopharmaceutical administration.
Neuroblastoma demand profile.
- Market is anchored in smaller incident counts, but high intensity of care and rare disease reimbursement can produce meaningful revenue per treated patient.
- Uptake depends on sequencing against anti-GD2 regimens and salvage chemotherapies.
PPGL demand profile.
- PPGL is rare; metastatic/unresectable and iodine-avid refractory subsets constrain eligible volume.
- Demand is sensitive to diagnostic imaging uptake protocols and referral patterns to centers equipped to administer radioiodinated agents.
Commercial takeaway.
- The market is not volume-driven. It is patient-selection-driven and site-availability-driven, with reimbursement and timing determining revenue realization.
Source anchor: Labeled indications that define the eligible population. [1]
When does iobenguane sulfate I 131 lose exclusivity or face generic entry risks?
Featured-snippet answer: There is no broad, reliable public basis in the provided materials to state specific patent expiration timelines or generic entry dates for iobenguane sulfate I 131.
Because patent estates are highly granular for radiopharmaceuticals (composition, radionuclide-specific formulations, manufacturing, dosing regimens, and process claims), market projection must typically use the Orange Book and litigation/patent assignment records for the specific US NDA/BLA and each listed patent. Those records are not included in the provided input set, so no precise exclusivity window can be stated here.
Practical business conclusion: Treat competitive risk as driven primarily by:
- competing radiopharmaceuticals (therapeutic substitutes)
- payer and guideline positioning changes
- site logistics and supply continuity
rather than near-term “generic” entry timing without validated patent and Orange Book data.
What patents protect iobenguane sulfate I 131 and what is the patent estate strength?
Featured-snippet answer: A defensible “how strong is the patent estate” assessment requires a complete US patent/Orange Book listing (and any related litigation dockets) for the specific Azedra NDA, including claim scope and remaining term. No such listing is present in the provided materials.
Implication for market forecasting.
- For radiopharmaceuticals, the most material barriers are often manufacturing/process and specific formulation/dosing claims rather than broad compound claims.
- Without a validated patent list and claim mapping, any quantitative strength scoring would be speculative.
Source anchor: FDA label is available, but it does not substitute for patent estate construction. [1]
What formulations and dosing methods are protected or matter competitively for iobenguane sulfate I 131?
Operational formulation dependencies.
- Radiopharmaceutical administration is dependent on:
- iodine-131 activity preparation
- thyroid blockade protocols
- patient preparation and pretreatment imaging
- radiation safety and handling constraints that influence throughput
Competitive relevance.
- Competitors often differentiate by:
- improved uptake and dosimetry predictability
- better tolerability profiles in targeted subsets
- logistics advantages (distribution, timing, imaging integration)
Evidence anchor: The FDA label contains key dosing and preparation instructions that define the “real-world product.” [1]
Which companies are competing with Azedra in neuroblastoma or PPGL radiopharmaceutical space?
Primary competition type. For Azedra, the closest competition in practice is not “another iobenguane generic.” It is typically:
- other radiopharmaceuticals in neuroendocrine oncology
- systemic therapies that displace radiopharmaceutical sequencing
Commercially relevant competitive set (category-level).
- anti-GD2 monoclonal antibodies and combination systemic regimens for neuroblastoma (for salvage and subsequent lines)
- chemotherapy and targeted approaches used after progression in relapsed/refractory neuroblastoma
- radioligands and radiopharmaceutical strategies used for iodine-avid or NET/PPGL subsets in PPGL
Business framing.
- Competitors win by influencing:
- clinical sequencing
- payer coverage
- patient selection via imaging and biomarkers
- center experience and radiopharmacy availability
Source anchor: Azedra’s labeled use defines where it competes within treatment pathways. [1]
What patent litigation or FDA regulatory events affect iobenguane sulfate I 131 commercialization?
Featured-snippet answer: The provided materials do not include patent litigation dockets, Paragraph IV filings, or FDA regulatory event timelines specific to iobenguane sulfate I 131. No litigation or event dates can be stated.
Market-impact logic (what typically moves the needle).
- settlement terms can delay or accelerate biosimilar/generic entry for related products
- REMS or label-change events can alter adoption patterns
- manufacturing or supply continuity issues can create utilization caps
Source anchor: None provided beyond FDA labeling. [1]
How does iobenguane sulfate I 131 compare with leading neuroblastoma and PPGL systemic and radiopharmaceutical options?
Comparison axes that drive share:
- Patient selection: iodine avidity and transport mechanism alignment.
- Efficacy depth and durability: objective response and survival metrics in refractory populations.
- Tolerability and cumulative toxicity: marrow suppression and general safety profile.
- Treatment logistics: need for nuclear medicine capabilities and scheduling.
- Sequencing advantage: ability to slot into lines of therapy without precluding subsequent options.
Regulatory posture effect.
- When clinical evidence is single-arm, clinicians and payers benchmark against shifting standard-of-care outcomes, which can compress or expand perceived comparative value.
Source anchor: Azedra label defines clinical use, preparation, and safety considerations. [1]
What is the commercial outlook for iobenguane sulfate I 131 through 2029–2034?
Forecast model structure (what a market pro forma must track).
- Treated patient count by indication
- dose frequency and repeat dosing patterns in label-based practice
- net price realization after discounts and payer concessions
- center expansion and referral growth
- competing therapy displacement rates
- supply continuity and radiopharmaceutical availability
Base-case commercial projection (directional).
- Growth is most likely driven by incremental:
- awareness and guideline inclusion
- center learning curve and scheduling efficiencies
- payer acceptance and evidence consolidation
- Structural headwinds include:
- displacement by newer systemic regimens and alternative radioligands
- limited eligible population and stringent selection
- high infrastructure dependence
Scenario approach (high level).
- Bull case: expanded access plus stable uptake in neuroblastoma and PPGL; slower competitive displacement.
- Base case: gradual adoption with share pressure from evolving standards of care.
- Bear case: stronger displacement by alternative radiopharmaceuticals or systemic regimens reduces eligible use.
Source anchor: Indications and dosing constraints from FDA labeling. [1]
Note: A quantified revenue forecast (USD value by year) cannot be produced from the provided materials because the input set lacks the necessary public data fields for treated volumes, net pricing, and competitor displacement rates.
Key Takeaways
- Azedra (iobenguane sulfate I 131) is FDA-approved for refractory/relapsed high-risk neuroblastoma (12+) and unresectable locally advanced or metastatic PPGL in iodine-avid refractory settings. [1]
- Market demand is patient-selection and center-capacity driven, not high-volume.
- Forecasting depends on real-world treated patient counts, net price realization, and sequencing dynamics against evolving neuroblastoma and PPGL standards of care.
- Specific exclusivity/expiration timelines and generic entry risk require the Orange Book patent listing and litigation records for the Azedra NDA, which are not included in the provided materials.
- Competitive risk is primarily therapeutic substitution rather than generic substitution.
FAQs
1) What imaging or selection criteria determine whether patients can receive iobenguane sulfate I 131?
Patient selection is driven by label-specified prerequisites, including iodine uptake considerations and preparation requirements outlined in prescribing information. [1]
2) How is iobenguane sulfate I 131 administered and what premedication is required?
The FDA label specifies dosing administration and thyroid blockade and preparation steps needed before treatment. [1]
3) In neuroblastoma, where does Azedra fit relative to anti-GD2 therapy and salvage chemotherapy?
Azedra is used in relapsed/refractory high-risk neuroblastoma populations after progression on standard therapies or when standard therapies are not suitable, making it a sequencing candidate after evolving salvage regimens. [1]
4) In PPGL, what makes patients eligible for Azedra treatment?
Eligibility is defined by unresectable locally advanced or metastatic PPGL status and refractoriness/progression context as described in the FDA label. [1]
5) Does iobenguane sulfate I 131 have any REMS or special distribution constraints that affect uptake?
The FDA label contains the controlling safety and administration requirements that typically govern distribution workflow and site readiness. [1]
References (APA)
- FDA. (n.d.). Azedra (iobenguane I 131) prescribing information / FDA label. U.S. Food and Drug Administration.
